What should a healthcare technology company look for when hiring a fractional CRO?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Healthtech Buying Committee Operates on a Clinical Hierarchy, Not a Corporate One

The buying committee in a healthcare technology company is structured around clinical authority, not organizational title. The attending physician or department chair holds de facto veto power over any technology that touches patient care, even if they have zero budget authority. The nursing director or clinical operations manager is the person who will actually use the product daily, and they can kill a deal by simply refusing to train their staff. The hospital's compliance officer reviews every contract for Stark Law and Anti-Kickback Statute implications, which means any pricing model that looks like a volume discount or a free trial period can trigger a legal review that takes 90 days. The purchasing department operates on a fiscal year calendar where budget allocations are locked in by October for the following year, so a deal proposed in November may not even be considered until the next budget cycle. Typical deal sizes in healthtech are not based on per-seat pricing; they are based on per-bed, per-discharge, or per-procedure metrics, with a single hospital system deal ranging from $75,000 to $400,000 in annual contract value depending on the number of facilities. Budget approval requires a formal "capital request" or "operational expense justification" that includes a five-year total cost of ownership analysis, a comparison to the existing workflow cost, and a letter of support from a clinical department head. Deals stall when the clinical champion goes on sabbatical, when the hospital announces a merger that freezes all vendor contracts, or when a new CMS reimbursement rule changes the financial incentive for the technology. A fractional CRO who has personally presented to a value analysis committee will know that the real decision is made in the 15 minutes before the meeting when the chief medical officer and the CFO discuss the proposal informally, not during the formal presentation.

The Sales Cycle in Healthtech Is a Series of Clinical Validations, Not Sales Stages

The sales cycle for a healthcare technology company is driven by clinical validation events, not by the sales rep's activity. The first validation is a "clinical champion interview" where the product is demonstrated to a department head who must believe it will not increase their malpractice risk. The second validation is a "pilot protocol" that defines exactly which patients, which clinicians, and which outcomes will be measured over a 30 to 60 day period. The third validation is a "peer reference call" with a clinician at another institution who has used the product and can vouch for its reliability. The fourth validation is a "legal and compliance review" that confirms the product does not violate any state-specific telehealth or data privacy laws. Ramp time for a new sales hire in healthtech is 9 to 15 months because they must learn the clinical workflow, build relationships with key opinion leaders, and understand the reimbursement landscape. Forecast behavior is unreliable because a deal can move from "pilot complete" to "board approval pending" to "on hold due to IT security audit" in a single week. Pipeline shape is heavily concentrated in the top 5% of accounts that represent multi-site health systems, but those accounts require a 12 to 18 month cultivation cycle from first contact to contract signature. The leaks are specific: deals die when the clinical champion leaves the organization (a 40% probability in any given year), when the pilot reveals a workflow integration issue that requires a product change, or when the hospital's IT department demands a data residency requirement that the company cannot meet. A fractional CRO must build a pipeline that includes a "fast track" for independent physician groups that can decide in 60 days, a "standard track" for community hospitals that take 6 to 9 months, and a "strategic track" for academic medical centers that take 12 to 18 months. The motion also forces a "clinical evidence accumulation" strategy where every pilot is designed to produce a case study or a white paper that can be used to close the next deal, because healthtech buyers do not trust vendor claims without published data.

What a Fractional CRO Must Bring: Clinical Informatics Fluency and Payer Reimbursement Knowledge

The fractional CRO for a healthcare technology company must have a background that includes direct experience with clinical informatics, meaning they understand how electronic health record systems like Epic or Cerner integrate with third-party applications and what the HL7 FHIR standard requires. They must also understand payer reimbursement models, specifically how Medicare Severity Diagnosis Related Groups (MS-DRGs) and Current Procedural Terminology (CPT) codes affect a hospital's willingness to pay for a technology that reduces length of stay or prevents readmissions. In the first 90 days, they will audit the company's clinical evidence package to ensure it includes at least one peer-reviewed study or a retrospective analysis of pilot data that shows a statistically significant improvement in a quality metric like 30-day readmission rate or door-to-balloon time. They will own the revenue architecture by defining the ideal customer profile not by company size but by clinical service line, such as "cardiology departments at 200+ bed community hospitals with a dedicated stroke center." They will set pricing that aligns with the hospital's reimbursement structure, such as a per-discharge fee for a readmission reduction tool or a per-procedure fee for a surgical planning platform. Their operating cadence includes a weekly "clinical pipeline review" where each deal is scored on the strength of the clinical champion's commitment, the status of the pilot protocol, and the timeline for the value analysis committee meeting. They advise on content marketing that targets specific clinical conferences like HIMSS, ACC, or RSNA, not general healthcare events. They own the sales compensation plan, which must include a "pilot completion bonus" that pays when the pilot protocol is executed, not just when the contract is signed, because healthtech deals often have a 60 to 90 day gap between contract and first payment. The signals to convert to full-time are when the company has closed at least 15 enterprise accounts across two distinct clinical specialties, has a predictable 90-day pipeline that shows a 3:1 ratio of pilots to full contracts, and the fractional CRO is spending more than 60% of their time on internal team development rather than external relationship building. If the company is still in the pre-revenue stage with fewer than 5 pilot customers, a fractional CRO is better suited as an advisor who helps design the clinical evidence strategy and closes the first 2 to 3 deals, then transitions to a full-time vice president of sales once the product-market fit is validated in a specific clinical workflow.

The First 90 Days: Audit the Clinical Evidence and the Pilot Infrastructure

The fractional CRO's first 30 days must be an audit of the company's clinical evidence and pilot infrastructure. They need to review the product's FDA clearance status, any IRB approvals for clinical studies, and the data security certifications that are required by hospital IT departments. They must interview the clinical advisory board to understand what objections they hear from their peers and what data would convince them to champion the product. The next 30 days are spent mapping the existing pipeline to the actual clinical validation process of each account. Most healthtech companies have a pipeline full of "active" deals that are actually stalled because the clinical champion has not yet built a business case that quantifies the return on investment in terms of reduced length of stay, increased procedure volume, or improved patient satisfaction scores. The fractional CRO must kill these deals or re-qualify them by requiring the champion to provide a written cost-benefit analysis that includes the hospital's specific reimbursement rates and staffing costs. The final 30 days are about building a 90-day sprint to close 2 to 3 pilot deals with independent physician groups or community hospitals that have a streamlined value analysis process. This sprint requires the fractional CRO to personally participate in the pilot design, ensuring that the protocol includes measurable clinical outcomes that can be published as a case study. The operating cadence includes a weekly "pilot review" where each active pilot is assessed on patient enrollment rates, data collection completeness, and clinician satisfaction scores, because a pilot that fails to enroll enough patients will not produce the evidence needed to close the full contract.

The Operating Cadence: Forecast Accuracy Depends on Clinical Milestones, Not Sales Activity

The fractional CRO must implement a forecasting system that tracks clinical milestones as the primary leading indicator. A deal is not "qualified" until the clinical champion has identified a specific patient population and a measurable outcome that the product will improve. A deal is not "committed" until the pilot protocol has been approved by the hospital's IRB or ethics committee, and the IT security review has been scheduled. A deal is not "closed" until the value analysis committee has approved the pricing and the legal team has signed the business associate agreement. The weekly forecast call should review three numbers: the number of clinical champions who have committed to a pilot protocol, the number of pilots that have enrolled at least 10 patients, and the number of contracts that are pending legal review. The pipeline shape must show a healthy ratio of 5:1 for pilot-stage deals to contract-stage deals, because only 20% of pilots will convert to full contracts within the first year. The leaks are predictable: deals stall when the clinical champion changes jobs (a 6-month setback), when the hospital system merges with another network (a 12-month reset), or when a competitor publishes a negative study about the product category. The fractional CRO must build a "clinical risk register" for each deal that flags these external events and triggers a contingency plan, such as identifying a backup champion at a different department within the same hospital or accelerating a pilot at a different site to generate alternative evidence.

The Signals to Convert or Keep Fractional: Clinical Segment Focus vs. Platform Exploration

The decision to convert a fractional CRO to full-time depends on whether the company has achieved revenue predictability within a specific clinical segment. If the company is selling to a single clinical specialty, such as radiology AI for stroke detection, and has closed 10 to 15 accounts with a repeatable sales motion that includes a 30-day pilot and a 60-day value analysis committee review, a full-time CRO can scale the team by hiring 3 to 5 enterprise sales reps and a clinical sales engineer. If the company is still exploring multiple clinical use cases, such as a platform that could serve both cardiology and oncology departments, a fractional CRO is better because they can pivot the sales strategy based on which buyer responds fastest and which clinical evidence is easiest to generate. The signals to keep fractional include: the company is pre-Series B and cannot afford a full-time CRO salary plus equity, the sales cycle is longer than 15 months and the fractional CRO is needed only for strategic advice on clinical evidence generation, or the company is entering a new clinical specialty and needs temporary market access expertise to build a pipeline in that segment. The signals to convert include: the fractional CRO is spending more than 35 hours per week on the role, the sales team is 5 or more people, and the company has a clear path to $7 million in ARR within 12 months based on a validated sales process in a single clinical specialty. The conversion should happen with a 90-day transition plan where the fractional CRO documents the clinical evidence requirements for each buyer persona, the pilot protocol templates, and the value analysis committee presentation deck, and then hands off their personal relationships with clinical champions to the new full-time hires.

FAQ

A question? How do you verify a fractional CRO's experience with hospital value analysis committees without a reference check? Ask them to describe the specific documents they prepared for a value analysis committee presentation, including the cost-benefit analysis template, the clinical evidence summary, and the implementation timeline. If they cannot name the exact format of a capital request form or the typical questions a CFO asks about total cost of ownership, they lack the depth needed. Also ask them to explain how they handled a situation where the committee asked for a 12-month pilot instead of a 3-month pilot, because that negotiation is a common hurdle in healthtech.

A question? What is the biggest mistake healthtech companies make when hiring a fractional CRO from outside the industry? They hire a fractional CRO who has sold to healthcare but not to hospital systems, such as someone who sold to pharmaceutical companies or medical device distributors. This mistake results in a sales process that focuses on clinical benefits without addressing the procurement and compliance requirements that hospital systems enforce. The CRO will not know how to structure a pilot that satisfies an IRB, how to negotiate a business associate agreement with a legal team that demands indemnification clauses, or how to price a subscription against a hospital's per-discharge reimbursement rate.

A question? How long should a fractional CRO engagement last for a healthtech company with no revenue? Typically 6 to 9 months, with a clear outcome-based contract that ties compensation to the completion of specific clinical pilots and the closing of the first 3 enterprise accounts. If the company has no clinical evidence or FDA clearance, the engagement should be 3 to 6 months focused on building the evidence package and designing the pilot protocol, not on active selling. If the company has a working product and at least one pilot site, the engagement can extend to 9 months to close the first 5 accounts and build a repeatable sales process.

A question? Can a fractional CRO work effectively for a healthtech company without being a clinician? Yes, but only if they have a deep understanding of clinical workflows and can speak fluently about specific medical conditions, procedures, and quality metrics. A non-clinician fractional CRO must have a clinical advisor on the team who can join sales calls and provide credibility. The risk is that the buyer will not trust a non-clinician's understanding of their workflow, especially if the product requires changes to how clinicians document patient care or interact with the electronic health record. The safest approach is to hire a fractional CRO who is a registered nurse, a physician assistant, or a former hospital administrator with direct patient care experience.

Sources